GPCR241220C22500
- 5.00
- -2.98-37.34%
Structure Therapeutics Newsroom
H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)
Promising Potential of Structure Therapeutics' ACCG-2671 Drives Buy Rating
Buy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment Platform
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%
The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.
The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.
Express News | Weight Loss Drug Developers Rise Intraday Trading After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Structure Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Hims & Hers Shares Tumble as FDA Resolves Obesity Drug Shortage
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy From Piper Sandler
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
Express News | Shares of Structure Therapeutics Fall 7.2%, Viking Therapeutics Fall 7.9%
Express News | Shares of Some Obesity Drug Developers Fall After Merck Signs up to $2 Bln Deal for Oral Obesity Drug
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Promising Prospects for Structure Therapeutics: Advancements in Amylin Drug Development and Strategic Positioning
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Raises Target Price to $91
Buy Rating on Structure Therapeutics: Promising Developments in GPCR's Oral Amylin-Based Drug and Broad Obesity Treatment Pipeline